Shares of Allergy Therapeutics plc (LON:AGY - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as GBX 7.50 ($0.09) and last traded at GBX 7.36 ($0.09), with a volume of 1111262 shares trading hands. The stock had previously closed at GBX 7.48 ($0.09).
Allergy Therapeutics Stock Performance
The company has a quick ratio of 1.48, a current ratio of 1.40 and a debt-to-equity ratio of 37.22. The stock has a fifty day moving average price of GBX 5.98 and a 200-day moving average price of GBX 5.19. The firm has a market cap of £351.07 million, a price-to-earnings ratio of -122.67, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.
Allergy Therapeutics Company Profile
(
Get Free Report)
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Articles
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
